StockData
CNS Pharmaceuticals, Inc. logo

CNS Pharmaceuticals, Inc. (CNSP) company profile

CNSPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$4.15+0.67 (+19.25%)

Close on Nov 17, 2026Market cap $6.07MP/E –Yield –

About CNS Pharmaceuticals

Pharmaceutical Preparations, SIC 2834

CNS Pharmaceuticals, Inc. is a biotechnology company focused on developing therapies for serious neurological conditions and cancers. The company seeks to build a portfolio of differentiated preclinical and clinical-stage drug candidates by identifying, acquiring, or in-licensing assets that offer defined biological rationales and clear regulatory pathways. Historically centered on advancing treatments for glioblastoma multiforme, including investigational compounds such as TPI 287 and Berubicin designed to cross the blood-brain barrier, the company has pivoted toward broader opportunities across neurology and oncology. Its primary target populations comprise patients diagnosed with severe neurodegenerative disorders and various oncological malignancies.

The company operates principally within the United States, maintaining its corporate headquarters in Houston, Texas. Its strategic activities encompass evaluating global asset acquisition and in-licensing opportunities across the worldwide biopharmaceutical sector. Development operations are led by an executive management team overseeing clinical, regulatory, and corporate initiatives.

Summary of the business section of CNS Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
CNS Pharmaceuticals, Inc.
Headquarters
Houston, TX
Address
2100 West Loop South, Suite 900 77027
Phone
1-800-946-9185
Employees
8, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Nevada
Fiscal year ends
December 31
Auditor
MaloneBailey, LLP, Houston, Texas

Stock & identifiers

Ticker
CNSP
Exchange
Nasdaq
IPO date
Nov 8, 2019
Shares outstanding
1M, Aug 11, 2026
Public float
$8.78M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-12 reverse, Jul 22, 2025; 1-for-50 reverse, Feb 21, 2025; 1-for-50 reverse, Jun 5, 2024; 1-for-30 reverse, Mar 31, 2023; 1-for-30 reverse, Nov 29, 2022
SEC CIK
1729427
CUSIP
18978H508
ISIN
US18978H5081
FIGI
BBG00PM24T16
Share class FIGI
BBG00PM24TS7
LEI
529900FDJ7WGF2Q7UN44
EIN
82-2318545

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
John M. ClimacoChief Executive Officer, Director215,676
Rami LevinCEO and President4,750
Eric FaulknerChief Technology Officer–
Steve O'LoughlinChief Financial Officer–
Christopher DownsChief Financial Officer103,438
Michal FisherDirector2,000
Faith L. CharlesDirector7,100
Jeffry R. KeyesDirector11,100
Bettina M. CockroftDirector–
Amy MaheryDirector–
Jerzy GumulkaDirector43,006

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$1.17M$964.58K$724.81K$0–
FY2024$1.10M$677.72K$982.69K$0–
FY2023$624.35K$846.87K$671.67K$53–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payTotalvs. prior year
John Climaco
Former Chief Executive Officer
$580.00K$269.59K$319.00K$1.17M+6%
Christopher Downs
Senior Vice President – Finance, (Former Chief Financial Officer)
$450.00K$134.81K$144.00K$728.81K+17%
Sandra Silberman
Former Chief Medical Officer
$495.00K$67.42K$158.40K$720.82K+99%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Nov 8, 2019
Offer price
$4.00
Securities offered
2,125,000
Gross proceeds
$8.50M
Exchange
Nasdaq
First trading day
Nov 8, 2019
First-day close
$4.57+14.3%
Lock-up ends (est.)
May 6, 2020

“Per Share Total Initial public offering price $ 4.00 $ 8,500,00 Underwriting discounts and commissions(1)(2) $ 0.28 $ 595,000 Proceeds to us, before expenses.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of March 31, 2026, we had eight full time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?